Bayer Pharma’s President Speaks of Results in the West and Prospects in Japan
This article was originally published in PharmAsia News
Executive Summary
At a press conference held in Osaka July 4, Bayer Pharma President Andreas Fibich revealed that oral Xa inhibitor Xarelto, which was introduced in Japan in April, held 14.2% of the German market share in June.